Close Menu

NEW YORK – OncoDNA and myNEO said on Wednesday that they have partnered to develop personalized, mRNA-based vaccines to treat advanced cancer patients.

Within the collaboration, the Belgium-based companies will use their respective technologies —OncoDNA's whole-genome and whole-transcriptome sequencing capabilities, and myNEO's artificial intelligence and bioinformatics capabilities — to identify targetable neoantigens in individual cancer patients and design mRNA-based vaccines that instruct their immune systems to go after those targets.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
08
Sponsored by
Qiagen

Cancer is a complex and heterogeneous disease requiring patient-specific molecular analysis to support treatment decisions.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.